In addition to myeloid leukemia, overexpression of EVI1 has been associated with aggressive phenotypes of breast cancer, colorectal, lung, ovarian, pancreatic, and prostate cancer [5,6,7,8,9,10,11,12,13]. Here, MECOM is linked to prostate cancer.